Obesity associated elevated leptin might contribute to paclitaxel resistance via PLCB1/IP3R1 axis in head and neck cancers.
BACKGROUND Head and neck cancer (HNC) is a heterogeneous malignancy with limited therapeutic success, largely due to its complex pathogenesis and high chemoresistance. Paclitaxel is commonly used in HNC therapy; however, the frequent development of resistance reduces its efficacy. Obesity has been linked to cancer prog...